Jaguar Health (NASDAQ:JAGX) Trading Up 9.8%

Jaguar Health Inc (NASDAQ:JAGX)’s share price was up 9.8% on Monday . The stock traded as high as $0.68 and last traded at $0.67, approximately 493,755 shares were traded during mid-day trading. A decline of 11% from the average daily volume of 552,685 shares. The stock had previously closed at $0.61.

Several analysts recently weighed in on JAGX shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective (down from $10.00) on shares of Jaguar Health in a report on Monday, November 18th. Zacks Investment Research lowered Jaguar Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. LADENBURG THALM/SH SH began coverage on Jaguar Health in a report on Thursday, September 12th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th.

The company has a quick ratio of 0.61, a current ratio of 0.88 and a debt-to-equity ratio of 0.61. The stock has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $1.79. The company has a market capitalization of $34.14 million, a price-to-earnings ratio of 0.00 and a beta of 0.68.

An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. bought a new stake in Jaguar Health Inc (NASDAQ:JAGX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned 0.05% of Jaguar Health as of its most recent SEC filing. 0.18% of the stock is currently owned by institutional investors.

Jaguar Health Company Profile (NASDAQ:JAGX)

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

See Also: What is the downside to momentum investing?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.